1
|
Trubacova R, Drastichova Z, Novotny J. Biochemical and physiological insights into TRH receptor-mediated signaling. Front Cell Dev Biol 2022; 10:981452. [PMID: 36147745 PMCID: PMC9485831 DOI: 10.3389/fcell.2022.981452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Accepted: 08/16/2022] [Indexed: 11/13/2022] Open
Abstract
Thyrotropin-releasing hormone (TRH) is an important endocrine agent that regulates the function of cells in the anterior pituitary and the central and peripheral nervous systems. By controlling the synthesis and release of thyroid hormones, TRH affects many physiological functions, including energy homeostasis. This hormone exerts its effects through G protein-coupled TRH receptors, which signal primarily through Gq/11 but may also utilize other G protein classes under certain conditions. Because of the potential therapeutic benefit, considerable attention has been devoted to the synthesis of new TRH analogs that may have some advantageous properties compared with TRH. In this context, it may be interesting to consider the phenomenon of biased agonism and signaling at the TRH receptor. This possibility is supported by some recent findings. Although knowledge about the mechanisms of TRH receptor-mediated signaling has increased steadily over the past decades, there are still many unanswered questions, particularly about the molecular details of post-receptor signaling. In this review, we summarize what has been learned to date about TRH receptor-mediated signaling, including some previously undiscussed information, and point to future directions in TRH research that may offer new insights into the molecular mechanisms of TRH receptor-triggered actions and possible ways to modulate TRH receptor-mediated signaling.
Collapse
|
2
|
Hachem LD, Mothe AJ, Tator CH. Effect of BDNF and Other Potential Survival Factors in Models of In Vitro Oxidative Stress on Adult Spinal Cord-Derived Neural Stem/Progenitor Cells. Biores Open Access 2015; 4:146-59. [PMID: 26309791 PMCID: PMC4497651 DOI: 10.1089/biores.2014.0058] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Transplantation of neural stem/progenitor cells (NSPCs) is a promising strategy in spinal cord injury (SCI). However, poor survival of transplanted stem cells remains a major limitation of this therapy due to the hostile environment of the injured cord. Oxidative stress is a hallmark in the pathogenesis of SCI; however, its effects on NSPCs from the adult spinal cord have yet to be examined. We therefore developed in vitro models of mild and severe oxidative stress of adult spinal cord-derived NSPCs and used these models to examine potential cell survival factors. NSPCs harvested from the adult rat spinal cord were treated with hydrogen peroxide (H2O2) in vitro to induce oxidative stress. A mild 4 h exposure to H2O2 (500 μM) significantly increased the level of intracellular reactive oxygen species with minimal effect on viability. In contrast, 24 h of oxidative stress led to a marked reduction in cell survival. Pretreatment with brain-derived neurotrophic factor (BDNF) for 48 h attenuated the increase in intracellular reactive oxygen species and enhanced survival. This survival effect was associated with a significant reduction in the number of apoptotic cells and a significant increase in the activity of the antioxidant enzymes glutathione reductase and superoxide dismutase. BDNF treatment had no effect on NSPC differentiation or proliferation. In contrast, cyclosporin A and thyrotropin-releasing hormone had minimal or no effect on NSPC survival. Thus, these models of in vitro oxidative stress may be useful for screening neuroprotective factors administered prior to transplantation to enhance survival of stem cell transplants.
Collapse
Affiliation(s)
- Laureen D Hachem
- Division of Genetics and Development, Krembil Neuroscience Centre, Toronto Western Hospital, University Health Network , Ontario, Canada
| | - Andrea J Mothe
- Division of Genetics and Development, Krembil Neuroscience Centre, Toronto Western Hospital, University Health Network , Ontario, Canada
| | - Charles H Tator
- Division of Genetics and Development, Krembil Neuroscience Centre, Toronto Western Hospital, University Health Network , Ontario, Canada . ; Department of Surgery, Division of Neurosurgery, University of Toronto , Ontario, Canada
| |
Collapse
|
3
|
Kinoshita K, Yamamura M, Sugihara J, Suzuki M, Matsuoka Y. Taltirelin Hydrate (TA-0910): An Orally Active Thyrotropin-Releasing Hormone Mimetic Agent with Multiple Actions. CNS DRUG REVIEWS 2006. [DOI: 10.1111/j.1527-3458.1998.tb00039.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
4
|
Kinoshita K, Watanabe Y, Asai H, Yamamura M, Matsuoka Y. Anti-ataxic effects of TRH and its analogue, TA-0910, in Rolling mouse Nagoya by metabolic normalization of the ventral tegmental area. Br J Pharmacol 1995; 116:3274-8. [PMID: 8719807 PMCID: PMC1909183 DOI: 10.1111/j.1476-5381.1995.tb15135.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
1. The mechanism of the anti-ataxic action of thyrotropin-releasing hormone (TRH) and its analogue. TA-0910, in the Rolling mouse Nagoya (RMN), an ataxic mutant mouse, has been investigated. 2. TRH (30 mg kg-1, i.p.) and TA-0910 (3 mg kg-1, i.p.) reduced the fall index (number of falls/spontaneous motor activity), an index of ataxia, 10-30 and 10-60 min after administration, respectively. 3. Relative local cerebral glucose utilization (LCGU) in the cerebellum and ventral tegmental area (VTA) of the rolling mouse was significantly smaller than that in normal animals. TRH (30 mg kg-1, i.p.) and TA-0910 (3 mg kg-1, i.p.) increased the relative LCGU value of the VTA but not of the cerebellum in rolling mice to the level of normal animals. 4. These results suggest that the ataxia of the rolling mouse may be due to dysfunction of the cerebellum and VTA, and that amelioration by TRH and TA-0910 could result from metabolic normalization of the VTA.
Collapse
Affiliation(s)
- K Kinoshita
- Pharmaceutical Development Research Laboratory, Tanabe Seiyaku Co., Ltd, Saitama, Japan
| | | | | | | | | |
Collapse
|
5
|
Kinoshita K, Fujitsuka T, Yamamura M, Matsuoka Y. Effects of TA-0910, a novel orally active thyrotropin-releasing hormone analog, on the gait of ataxic animals. Eur J Pharmacol 1995; 274:65-72. [PMID: 7768282 DOI: 10.1016/0014-2999(94)00712-g] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The effects of TA-0910 (1-methyl-(S)-4,5-dihydroorotyl-L-histidyl-L- prolinamide), a new thyrotropin-releasing hormone (TRH: L-pyroglutamyl-L-histidyl-L-prolinamide) analog, on ataxia were compared with those of TRH given by oral administration. The ataxic models used were the Rolling mouse Nagoya (RMN) showing genetic dysfunction of the cerebellum and striatum, rats with chemical degeneration of the inferior olive induced by 3-acetylpyridine (3-AP, 40 mg/kg, i.p.) and rats with a lesion of the thoracic spinal cord induced by mechanical compression. TA-0910 (1, 3, 10 mg/kg per day) clearly showed ameliorating effects on all these ataxic models. The dose-dependent effect of TA-0910 (10 mg/kg per day) on the gait of RMN was sustained until 2 weeks after the end of its 2-week administration. TRH (100, 300 mg/kg per day) also showed ameliorating effects on ataxia in RMN and 3-AP-treated rats. The ameliorating action of TA-0910 on ataxia was 100-300 times more potent than that of TRH.
Collapse
Affiliation(s)
- K Kinoshita
- Pharmacological Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama, Japan
| | | | | | | |
Collapse
|
6
|
Kinoshita K, Nagao T, Ono H. Effects of TA-0910, an orally active TRH analog, on the spinal reflex in spinal rats. Neuropharmacology 1994; 33:1183-8. [PMID: 7862253 DOI: 10.1016/s0028-3908(05)80008-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Effects of TA-0910 (1-methyl-(S)-4,5-dihydroorotyl-L-histidyl-L-prolinamide), a new thyrotropin releasing hormone (TRH) analog, on spinal reflex potentials and flexor reflexes were compared with those of TRH in C1-spinal rats. Intravenously administered TA-0910 and TRH produced dose-dependent increases in the amplitudes of mono- and polysynaptic reflex potentials and withdrawal flexor reflexes. TA-0910 was more potent and more long-lasting than TRH. The stimulating actions of TA-0910 and TRH on the monosynaptic reflex potential were not antagonized by pretreatment with atropine, cyproheptadine, haloperidol or prazosin, suggesting no involvement of the cholinergic, serotonergic, dopaminergic or noradrenergic system. Intraduodenally administered TA-0910 also produced a lasting potentiation of the withdrawal flexor reflex, but intraduodenally administered TRH showed no effect. These results suggest that TA-0910 may be a more useful drug than TRH for spinal functional disorders.
Collapse
Affiliation(s)
- K Kinoshita
- Pharmacological Research Laboratory, Tanabe Seiyaku Co. Ltd., Saitama, Japan
| | | | | |
Collapse
|
7
|
Akdemir H, Paşaoğlu H, Arman F, Coksevim B, Paşaoğlu A. Effects of TRH and high-dose corticosteroid therapy on evoked potentials, and tissue Na+,K+ and water content in experimental spinal injury. RESEARCH IN EXPERIMENTAL MEDICINE. ZEITSCHRIFT FUR DIE GESAMTE EXPERIMENTELLE MEDIZIN EINSCHLIESSLICH EXPERIMENTELLER CHIRURGIE 1993; 193:297-304. [PMID: 8278676 DOI: 10.1007/bf02576237] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The therapeutic effects of continuous infusion of thyrotropin-releasing hormone (TRH) and methylprednisolone (MP) in experimental spinal cord injury were studied in Swiss albino rats. Thirty rats received a 53-g clip-compression injury on the cord at T1, then were allocated randomly and blindly to one of three treatment groups (ten animals in each): (1) control; received equal volumes of saline solution; (2) MP; received 30 mg/kg methylprednisolone i.v. 1h after trauma, followed by infusion of 5.4 mg/kg/per hour i.v. for 3h; (3) TRH; received 2 mg/kg TRH i.v. 1h after trauma, followed by infusion of 1 mg/kg/per hour i.v. for 3h. MP and TRH treatments significantly improved somatosensory-evoked potentials (SEPs; P < 0.001). Both treatments significantly reduced water content, decreased Na+ content and increased the K+ content of the cord segment that included the centre of the impact (P < 0.01). Our data provide evidence for the beneficial effects of high-dose corticosteroid and TRH in promoting electrophysiological recovery and preserving spinal cord tissue following experimental injury.
Collapse
Affiliation(s)
- H Akdemir
- Department of Neurosurgery, Erciyes University, School of Medicine, Kayseri, Turkey
| | | | | | | | | |
Collapse
|
8
|
Hashimoto T, Wada T, Fukuda N, Nagaoka A. Effect of thyrotropin-releasing hormone on pentobarbitone-induced sleep in rats: continuous treatment with a sustained release injectable formulation. J Pharm Pharmacol 1993; 45:94-7. [PMID: 8095539 DOI: 10.1111/j.2042-7158.1993.tb03690.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The mode of action and the time course of the effects of continuous thyrotropin-releasing hormone (TRH) treatment using a two-week sustained release injectable formulation of TRH-containing copoly((+/-)-lactic/glycolic acid) microspheres (TRH-SR) on pentobarbitone-induced sleeping time were studied in rats. Subcutaneous treatment with TRH-SR at doses corresponding to 0.05 and 0.2 mg of TRH kg-1 day-1 caused a dose-related shortening of pentobarbitone-induced sleeping time with a minimum effective dose (MED) of 0.05 mg kg-1 day-1, without affecting the body weight gain. On the other hand, the MED of TRH when given as a bolus subcutaneous injection was 40 mg kg-1. The effect of TRH-SR treatment was blocked by intraperitoneal scopolamine (0.1 mg kg-1) and mecamylamine (2 mg kg-1) but not by scopolamine methyl bromide (0.1 mg kg-1). The results indicate that continuous TRH treatment using TRH-SR causes shortening of pentobarbitone-induced sleeping time at doses lower than those required using bolus injection and probably by a mechanism involving the central cholinergic system.
Collapse
Affiliation(s)
- T Hashimoto
- Research and Development Division, Takeda Chemical Industries Ltd., Osaka, Japan
| | | | | | | |
Collapse
|
9
|
Akdemir H, Paşaoğlu A, Oztürk F, Selçuklu A, Koç K, Kurtsoy A. Histopathology of experimental spinal cord trauma. Comparison of treatment with TRH, naloxone, and dexamethasone. RESEARCH IN EXPERIMENTAL MEDICINE. ZEITSCHRIFT FUR DIE GESAMTE EXPERIMENTELLE MEDIZIN EINSCHLIESSLICH EXPERIMENTELLER CHIRURGIE 1992; 192:177-83. [PMID: 1636062 DOI: 10.1007/bf02576273] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The results of treatment with thyrotropin-releasing hormone (TRH), naloxone and dexamethasone treatments albino rats with experimental spinal cord injury were compared. All the animals were made paraplegic by the application clip method of Rivlin and Tator. Treatment was administered i.p. as bolus injections in two doses, at 45 and 120 min after the injury. Animals were allocated randomly to four experimental groups: (1) TRH (0.6 mg per dose), (2) naloxone (0.8 mg per dose), (3) dexamethasone (0.6 mg per dose), and (4) control (saline). TRH-treated rats showed significantly better histopathological scores than either naloxone or dexamethasone-treated ones (Kruskal Wallis: 24.058 P less than 0.001).
Collapse
Affiliation(s)
- H Akdemir
- Department of Neurosurgery, Erciyes University Medical School, Kayseri, Turkey
| | | | | | | | | | | |
Collapse
|
10
|
Hashimoto T, Fukuda N. Effect of thyrotropin-releasing hormone on the neurologic impairment in rats with spinal cord injury: treatment starting 24 h and 7 days after injury. Eur J Pharmacol 1991; 203:25-32. [PMID: 1797554 DOI: 10.1016/0014-2999(91)90786-p] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The effect of treatment with thyrotropin-releasing hormone (TRH) or naloxone on the neurologic impairment after spinal cord injury was studied in rats with the severest neurologic impairment (complete paraplegia, no withdrawal response upon tail pinching, and urinary incontinence) 24 h and 7 days after injury. Subcutaneous treatment with TRH (2.5, 10 and 40 mg/kg per day) once daily for 7 consecutive days starting 24 h or 7 days after injury improved the neurologic function in the rats with cord injury in a dose-related manner, with a minimum effective dose of less than 2.5 mg/kg per day in both cases. However, subcutaneous treatment with naloxone (40 mg/kg per day) once daily for 7 consecutive days starting 24 h after injury did not exert any beneficial effects on neurologic function. These results indicate that TRH but not naloxone treatment starting 24 h and as late as 7 days after injury is effective in rats with the severest neurologic impairment following spinal cord injury. Thus, it is suggested that the duration of the effectiveness of late treatment with TRH on the neurologic impairment in rats with spinal cord injury is more than 1 week, while the duration with naloxone is less than 24 h.
Collapse
Affiliation(s)
- T Hashimoto
- Research and Development Division, Takeda Chemical Industries, Ltd., Osaka, Japan
| | | |
Collapse
|
11
|
Hashimoto T, Fukuda N. Contribution of serotonin neurons to the functional recovery after spinal cord injury in rats. Brain Res 1991; 539:263-70. [PMID: 1829012 DOI: 10.1016/0006-8993(91)91630-j] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The contribution of serotonin neurons to the functional recovery after spinal cord injury was studied pharmacologically in rats with moderately severe neurologic impairment (complete paraplegia but responsive to tail pinching) 24 h after thoracic spinal cord (T11) compression-induced injury. Fourteen days after cord injury the levels of endogenous norepinephrine (NE, -33%), dopamine (DA, -50%) and serotonin (5-HT, -55%) in the lumbar cord in the injury control rats were decreased and there were significant correlations between the neurologic score and the NE level (rs = 0.562, P less than 0.01) and the 5-HT level (rs = 0.745, P less than 0.001) but not the DA level. Bilateral i.c.v. injection of 5,7-dihydroxytryptamine (200 micrograms/rat) 24 h after cord injury significantly retarded the neurologic recovery during the 14 days after injury, accompanied by a further reduction in the 5-HT level (-86%) but not in the NE or DA level. On the other hand, neither p-chlorophenylalanine (PCPA) (300 mg/kg, i.p., once daily starting 24 h after injury for 13 consecutive days) nor reserpine (1 mg/kg, i.p., 4 times, once 24 h after injury and then every fourth day) had any influence on the time course of the neurologic recovery during the 14 days after injury, although PCPA treatment further reduced the levels of NE (-50%) and 5-HT (-91%), and reserpine treatment further reduced the levels of NE (-95%), DA (-73%) and 5-HT (-85%).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- T Hashimoto
- Research and Development Division, Takeda Chemical Industries, Ltd., Osaka, Japan
| | | |
Collapse
|